Pascale Richetta - UCB SA President
UCBJY Stock | USD 58.22 1.22 2.14% |
President
Ms. Pascale Richetta has served as Executive Vice President, Bone Patient Value Unit Head, Member of the Executive Committee of UCB S.A. since February 1, 2016. She has over 20 years of experience in the pharma and biotech industry. She has acquired commercial experience managing both traditional pharmaceuticals and complex biologics. Her experience and knowledge of markets around the world is key to helping UCB prepare for future product launches. Trained as a medical doctor, Pascale Richetta leads UCBs Bone Patient Value Unit. One of her main missions is to take UCBs investigational osteoporosis drug through the next steps in its development and prepare for its potential launch upon approval. Key positions Prior to UCB, Pascale held the following positions 2013 Present AbbVie Vice President, Western Europe and Canada In charge of a multibillion specialty care portfolio including key biologic products Covering 19 affiliates and over 3000 staff 2004 2013 Abbott Vice President, Western Europe and Canada 1994 2004 GSK Operations Director in France and Europe in charge of the Central Nervous System franchise 19901994 Ipsen Marketing Manager, France 19871990 Product Manager, France. Education 1985 Universite de Poitiers, France M.D. Prior trade association engagement EFPIA Vice Chair of the Executive Committee, member of the Board EBE Member of the Board Europa BIO Member of the Board. since 2016.
Age | 59 |
Tenure | 8 years |
Phone | 32 2 559 99 99 |
Web | https://www.ucb.com |
UCB SA Management Efficiency
The company has return on total asset (ROA) of 0.0468 % which means that it generated a profit of $0.0468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1069 %, meaning that it generated $0.1069 on every $100 dollars invested by stockholders. UCB SA's management efficiency ratios could be used to measure how well UCB SA manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | PRESIDENT Age | ||
Kasper Poulsen | Novo Nordisk AS | N/A | |
Karsten Knudsen | Novo Nordisk AS | 53 | |
Thomas Graney | Vertex Pharmaceuticals | 52 | |
Douglas McCorkle | Regeneron Pharmaceuticals | 58 | |
Peter Ankersen | Novo Nordisk AS | N/A | |
Rod Bristow | Pearson PLC ADR | 62 | |
Kimberly White | Vertex Pharmaceuticals | N/A | |
Ludovic Helfgott | Novo Nordisk AS | 50 | |
Paul Silva | Vertex Pharmaceuticals | 51 | |
Ian Smith | Vertex Pharmaceuticals | 51 | |
Jay Markowitz | Regeneron Pharmaceuticals | N/A | |
Camilla Sylvest | Novo Nordisk AS | 52 | |
John Gray | Vertex Pharmaceuticals | 53 | |
Bob Whelan | Pearson PLC ADR | 71 | |
Amit Sachdev | Vertex Pharmaceuticals | 50 | |
Michael Partridge | Vertex Pharmaceuticals | N/A | |
Kaare Schultz | Novo Nordisk AS | 52 | |
Tom Waldron | Pearson PLC ADR | N/A | |
Charles Wagner | Vertex Pharmaceuticals | 56 | |
Christopher Fenimore | Regeneron Pharmaceuticals | 53 | |
Henrik Wulff | Novo Nordisk AS | 54 |
Management Performance
Return On Equity | 0.11 | |||
Return On Asset | 0.0468 |
UCB SA ADR Leadership Team
Elected by the shareholders, the UCB SA's board of directors comprises two types of representatives: UCB SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of UCB. The board's role is to monitor UCB SA's management team and ensure that shareholders' interests are well served. UCB SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, UCB SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
Pascale Richetta, Executive Vice President Bone Patient Value Unit Head, Member of the Executive Committee | ||
Detlef Thielgen, CFO and Executive VP | ||
Kay Davies, Independent Director | ||
Dirk Teuwen, VP Corporate Societal Responsibility | ||
Anna Richo, Executive VP and General Counsel | ||
Viviane Monges, Independent Non-Executive Director | ||
Gerhard Mayr, Non-Executive Chairman of the Board | ||
Cyril Janssen, Director | ||
Caroline Vancoillie, Chief Functions | ||
Cedric Rijckevorsel, Director | ||
JeanChristophe Tellier, Chairman of the Executive Committee, CEO | ||
Arnoud Calesberg, Non-Executive Director | ||
Mark McDade, COO and Executive VP | ||
Xavier Michel, Vice President and Secretary General | ||
Dhavalkumar Patel, Executive Vice President Chief Scientific Officer, Member of the Executive Committee | ||
Bharat Tewarie, Executive Vice President Chief Marketing Officer | ||
Roch Doliveux, Chairman of the Executive Committee, CEO, Executive Director | ||
Norman Ornstein, Non-Executive Independent Director | ||
Jeff Wren, Executive Vice President Neurology – Patient Value Unit Head | ||
JeanPierre Kinet, Non-Executive Independent Director | ||
Antje Witte, VP of Investor Relations | ||
Alice Dautry, Independent Director | ||
Sandrine CFA, Ex CFO | ||
Harriet Edelman, Non-Executive Independent Director | ||
Ulf Wiinberg, Independent Director | ||
William Silbey, Exec Counsel | ||
Thomas McKillop, Non-Executive Independent Director | ||
Charl Zyl, Executive Vice President Head of Patient Value Operations, Member of the Executive Committee | ||
France Nivelle, VP Global Communication | ||
Fabrice Enderlin, Executive Vice President - Human Resources & Communication, Member of the Executive Committee | ||
Pierre Gurdjian, Independent Director | ||
Ismail Kola, Chief Scientific Officer, Head of New Medicines Patient Value Unit and Executive VP | ||
Emmanuel Caeymaex, Executive Vice President Immunology - Patient Value Unit Head | ||
Evelyn Bergendal, Non-Executive Vice Chairwoman of the Board | ||
Iris LoewFriedrich, Executive Vice President Chief Medical Officer | ||
CharlesAntoine Janssen, Non-Executive Director | ||
Pr LowFriedrich, Chief VP | ||
Kirsten LundJurgensen, Ex Solutions | ||
Albrecht Graeve, Non-Executive Independent Director | ||
JeanLuc Fleurial, Executive Vice President Chief Talent Officer, Member of the Executive Committee | ||
Alexander Moscho, Executive Vice President Chief Strategy Officer, Member of the Executive Committee |
UCB Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is UCB SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.11 | |||
Return On Asset | 0.0468 | |||
Profit Margin | 0.15 % | |||
Operating Margin | 0.19 % | |||
Current Valuation | 16.62 B | |||
Shares Outstanding | 379.92 M | |||
Price To Earning | 17.55 X | |||
Price To Book | 1.55 X | |||
Price To Sales | 2.54 X | |||
Revenue | 5.78 B |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards UCB SA in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, UCB SA's short interest history, or implied volatility extrapolated from UCB SA options trading.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.ABBV | AbbVie Inc | |
HBI | Hanesbrands | |
MIDU | Direxion Daily Mid |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UCB SA ADR. Also, note that the market value of any Company could be tightly coupled with the direction of predictive economic indicators such as signals in inflation. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Complementary Tools for UCB Pink Sheet analysis
When running UCB SA's price analysis, check to measure UCB SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy UCB SA is operating at the current time. Most of UCB SA's value examination focuses on studying past and present price action to predict the probability of UCB SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move UCB SA's price. Additionally, you may evaluate how the addition of UCB SA to your portfolios can decrease your overall portfolio volatility.
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum |